BICL Insider Trading Activity and SEC Form 4 Filings
BICL insider trading summary
No open-market insider purchases or sales of Biocancell Therapeutics Inc. (BICL) have been reported on SEC Form 4 in the past 12 months.
Latest BICL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 31, 2012 | Clal Biotechnology Industries Ltd. | 10% Owner | Buy | $2.3M (10,731,726 @ $0.22) |
| Jan 24, 2012 | Ruth Manor | 10% Owner | Buy | $2.1M (8,199,400 @ $0.26) |
| Jan 24, 2012 | Clal Industries & Investments Ltd | 10% Owner | Buy | $2.1M (8,199,400 @ $0.26) |
| Jan 24, 2012 | Idb Development Corp Ltd | 10% Owner | Buy | $2.1M (8,199,400 @ $0.26) |
| Jan 24, 2012 | Clal Biotechnology Industries Ltd. | 10% Owner | Buy | $2.1M (8,199,400 @ $0.26) |
| Jan 24, 2012 | Nochi Dankner | 10% Owner | Buy | $2.1M (8,199,400 @ $0.26) |
| Jan 24, 2012 | Avraham Livnat | 10% Owner | Buy | $2.1M (8,199,400 @ $0.26) |
| Jan 24, 2012 | Shelly Bergman | 10% Owner | Buy | $2.1M (8,199,400 @ $0.26) |
| Jan 24, 2012 | Idb Holding Corp Ltd | 10% Owner | Buy | $2.1M (8,199,400 @ $0.26) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.